NCT05293223 - Phase IIB Study of Recombinant Novel Coronavirus Vaccine | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

November 15, 2022

Study Completion Date

December 15, 2023

Conditions

COVID-19 Vaccine

Interventions

BIOLOGICAL

Ad5-nCov

Participants enrolled in Group A with only the 1st dose of Sputnik V will receive Ad5-nCoV vaccine at least 21 days but no more than 180 days after the first dose. They will be followed to evaluate the immunogenicity and safety of Ad5-nCoV vaccine during 6 months

Trial Locations (3)

1119

Centro de Investigación y Prevención Cardiovascular CIPREC, Buenos Aires

1202

Fundación Huésped, Ciudad Autónoma de Buenos Aires

1414

Centro de vacunación PREVIVAX, Ciudad Autonoma de Buenos Aire